Astaxanthin Boosts Cycling Endurance by 18% in Just 4 Days
Short-term astaxanthin supplementation significantly enhanced cycling performance while reducing muscle damage and oxidative stress in young adults.
Summary
Researchers tested whether 4 days of astaxanthin supplementation could improve cycling performance in young men. Ten physically active college students took either 28mg astaxanthin or placebo daily, then cycled to exhaustion at 75% maximum oxygen uptake. Astaxanthin increased time to exhaustion by 18% (85 vs 72 minutes) and significantly reduced muscle damage markers like creatine kinase and oxidative stress indicators. The supplement also decreased lipid peroxidation during exercise without affecting mood or causing side effects, suggesting astaxanthin could be a practical ergogenic aid for endurance athletes.
Detailed Summary
This randomized controlled crossover trial investigated whether short-term astaxanthin supplementation could enhance endurance performance and reduce exercise-induced damage in young adults. The study addresses a key gap in sports nutrition research, as previous astaxanthin studies showed mixed results with varying doses and durations.
Ten physically active male college students (age 22.5±0.9 years) completed both astaxanthin and placebo trials in randomized order with a one-week washout period. Participants consumed 28mg astaxanthin daily (seven 4mg capsules) or matching placebo for four days, then performed exhaustive cycling at 75% VO2max on day four. Blood samples were collected before, during (20 and 40 minutes), and immediately after exercise to measure muscle damage, inflammation, and oxidative stress markers.
Astaxanthin produced remarkable performance improvements. Time to exhaustion increased significantly from 72.11±2.24 minutes with placebo to 85.41±4.42 minutes with astaxanthin (P<0.001, effect size η²p=0.71). This represents an 18% performance enhancement. Muscle damage markers were substantially reduced: creatine kinase and lactate dehydrogenase release were significantly lower with astaxanthin (P<0.05), with a significant time-treatment interaction for creatine kinase (P=0.039, η²p=0.217). Oxidative stress, measured by malondialdehyde levels, was also significantly inhibited during and after exercise (P<0.05).
Interestingly, inflammatory markers (TNF-alpha, C-reactive protein) showed no response to either supplementation or exercise, and substrate utilization patterns remained similar between trials. Mood profiles were unaffected, confirming astaxanthin's safety profile. The researchers noted this was the first study testing 28mg daily astaxanthin for only four days, making it highly practical for athletes seeking rapid performance benefits. However, the study was limited to young, physically active males, and longer-term effects remain unknown.
Key Findings
- Time to exhaustion increased 18% from 72.1 minutes (placebo) to 85.4 minutes (astaxanthin) with large effect size (P<0.001, η²p=0.71)
- Creatine kinase release significantly reduced with astaxanthin supplementation (P<0.05) indicating less muscle damage
- Lactate dehydrogenase levels significantly decreased with astaxanthin treatment (P<0.05)
- Lipid peroxidation (malondialdehyde) substantially inhibited during and after exercise with astaxanthin (P<0.05)
- No adverse effects on mood profile or side effects reported with 28mg daily dose for 4 days
- Inflammatory markers (TNF-alpha, C-reactive protein) showed no response to either treatment or exercise
- Substrate utilization patterns remained similar between astaxanthin and placebo trials
Methodology
Randomized, single-blind crossover trial with 10 physically active male college students (age 22.5±0.9 years). Participants consumed 28mg astaxanthin or placebo daily for 4 days, then performed exhaustive cycling at 75% VO2max. One-week washout period between trials. Blood samples collected at 5 timepoints for biomarker analysis. Power analysis confirmed adequate sample size with effect size of 3.47.
Study Limitations
Study limited to young, physically active males only, limiting generalizability to other populations. Short 4-day intervention period means longer-term effects unknown. Small sample size (n=10) despite adequate statistical power. No assessment of astaxanthin blood levels to confirm absorption. Single-blind design may introduce some bias.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.